Review the early symptoms of Parkinson’s disease (PD) in order to establish diagnosis sooner in the process.

Revisit the short and long-term data of novel therapies for the treatment of tardive dyskinesia that have been FDA approved in the past 18-months and compare with existing non-FDA approved therapies with regard to efficacy/safety.

Discuss the prevalence and diagnostic criteria for TD in psychiatric patients.

Identify the neurologic, autonomic, cardiac symptoms of hATTR amyloidosis in the context of the differential diagnosis for hATTR amyloidosis

This activity is designed to meet the educational needs of neurologists, internists, family physicians, primary care clinicians, physician assistants, nurse practitioners, nurses, and pharmacists involved in the care of patients with MS.